The following is the list of publications and abstracts that Dr Dore has been involved with:

• Dore RK. Should healthy people take calcium and vitamin D to prevent fractures? What the US Preventive Services Task Force and others say. Cleveland Clinic Journal of Medicine, 80:6 2013 Jun pg 341-344
• Dore RK. Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Patient preference and adherence, May 2013, Volume 7: 2013 pg 435-446.
• Dore RK. Data from extension trials: denosumab and zoledronic acid. Current Osteoporosis Reports, Mar 2012, Volume 10(1): Pages 16-21.
• Dore RK. The RANKL Pathway and Denosumab. Rheumatic Disease Clinics of North America, Aug 2011, Volume 37, Issue 3, Pages 433-452. Review.
• Deohar A, Dore R, Et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.  Arthritis Care & Research, Volume 62(4):569-574, Apr 2010.
• Dore, RK. How to prevent glucocorticoid-induced osteoporosis. Cleve Clin J Med 2010; 77:529-536.
• Dore RK. The gout diagnosis. Cleve Clin J Med. 2008 July;75 Suppl 5:S 17-21. Review.
• Cohen SB, Dore RK, Lane et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008 May;58(5): 1299-309.
• Lane N, Cohen S, Dore R et al. Denosumab Increases Bone Mineral Density in Patients With Glucocorticoid-Induced Bone Loss and Rheumatoid Arthritis.  Submitted ACR 2007
• Nevitt MC, Chen P, Dore RK, et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporosis Int. 2006 Feb; 17(2):273-80. Epub 2005 Sep 2. Review.
• Tesser J, Fleischmann R, Dore RK, et al. Concomitant medication use in a large, international multicenter, placebo controlled trial of anakinra,  a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol. 2004 Apr;31 (4):649-54.
• Krueger K, Lino L, Dore R et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).  Ann Rheum Dis 2007, Published Online First: 27 October 2007.
• Dore R et al. Denosumab Increases Bone Mineral Density in Patients With Rheumatoid Arthritis: 12-month Results. Oral presentation. ASBMR 2007
• Dore RK et al. Inhibiting RANKL with Denosumab Increases Bone Mineral Density in Patients with Rheumatoid Arthritis: 6-month results from a randomized, placebo-controlled study.  Poster EULAR 2007
• Dore RK et al. The Immunogenicity, Safety, and Efficacy of Etanercept Liquid Administered Once Weekly in Patients with Rheumatoid Arthritis. Clin Exp Rheumatol. 2007;25:40-6.
• Dore RK et al. RANKL Inhibition with Denosumab Increases Bone Mineral Density in Patients with Rheumatoid Arthritis.  ECCEO 2007 Porto, Portugal  Abstract  #138.
• Bird H, Green C et al. [US Consultant: Dore RK].  Arthritis: your comprehensive guide to pain management, medication, diet, exercise, surgery, and physical therapies. 2006. DK Publishing, New York.
• Nevitt MC, Chen P, Kiel DP,  Reginster J-Y, Dore RK et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: A meta-analysis. 2006 Osteoporos Int 17(11):1630-1637
• Dore RK et al.  Denosumab Increases Bone Mineral Density in Patients With Rheumatoid Arthritis. Poster SU321, ACR WashingtonDC.  November 2006.
• Dore RK. Reasons for Patient Preferences for Once-Monthly Ibandronate. Poster P458SU, ASBMR Philadelphia, PA September 2006.
• Dore RK. Patient Preferences with a Once-Monthly Bisphosphonate. Poster P458SU, World Congress on Osteoporosis, Toronto, June 2006.
• Nevitt MC, Chen P, Dore RK et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis.  2006 Osteoporos Int 17(2):273-280.
• Dore R, et al.  Liquid Enbrel Improves Function and Health Related Quality of Life for Patients with Rheumatoid Arthritis. 2005 EULAR. Poster. Vienna, Austria.
• Dore RK. The Use of Parathyroid Hormone in Patients with Rheumatic Diseases, in Maricic MJ, Gluck O, Bone Disease in Rheumatology, Lippincott Williams & Wilkins, Philadelphia PA 2004.
• RK Dore, et al. The Safety and Efficacy Profile of Etanercept (ENBREL) Liquid Administered Once Weekly in Patients With Rheumatoid Arthritis. 2004 ACR Annual Scientific Meeting, San AntonioTX. Poster Presentation 1479.
• RK Dore, et al. Reduced Risk of Back Pain following Teriparatide Treatment: A Meta-analysis. 2004 ACR Annual Scientific Meeting, San AntonioTX. Poster Presentation 672.
• RK Dore, JH Krege, P Chen et al.  Reduction in Back Pain following Teriparatide compared with Alendronate treatment of postmenopausal women with osteoporosis  31st European Symposium on Calcified Tissues Nice, France, 5-9 June 2004
• Tesser J, Fleischmann R, Dore R et al.; 990757 Study Group.  Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol. 2004 Apr;31(4):649-54.
• Body J-J, Gaich GA, Scheele WH, Kulkarni, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.  A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] to alendronate in postmenopausal women with osteoporosis.  J Clin Endocrinol Metab. 2002;87(10):4528-4535.
• Tesser J, Schectman J, Dore R et al for the 757 Study Group. The safety of anakinra in combination with other RA therapies. EULAR 2002; FR10048
• Fife R, Chase WF, Dore RK et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med. 2002 Jun 10;162(11):1293-300
• Dore RK, Osteoporosis: Fractures and Key Risk Factors, Female Patient 2002; March Supp:5-12.
• Dore RK, Hodsman AB, et al.  Changes in Bone Mineral Density 18 Months After Cessation of Recombinant Human Parathyroid Hormone (1-34) or Alendronate Treatment in Postmenopausal Women. Poster ACR San Francisco 2001.
• Locks CD, Dore RK.   Developing Medical Documentation for Rheumatology Encounters, in Weisman M, Weinblatt M, Louie J., Treatment of the Rheumatic Disease, 2^nd Edition, WB Saunders, PhiladelphiaPA 2001.
• Dore RK, et al.  Guidelines for Rheumatology Referral, AmericanCollege of Rheumatology, 1996
• Dore RK, et al.  Efficacy and Safety of Etodolac and Naproxen in Patients with Osteoarthritis of the Knee:  A Double-Blind, Placebo Controlled Study, Clinical Therapeutics, Vol. 17, No 4, 656-666, 1995.
• Editorial: Marder WD, Meenan RF, Felson DT, Reichlin M, BirnbaumNS, Croft JS, Dore RK, Kaplan H, Kaufman RL, Stobo J: “The Present and Future Adequacy of Rheumatology Manpower: A Study of Health Care Needs and Physician Supply”.  Arthritis and Rheumatism, 34:10 1209-1217, October 1991.
• Dore RK, Nies, KM, Iwaki Y, Louie JS, Terasaki P: “A Profile of Lymphocytotoxic Antibodies in Systemic Lupus Erythematosus”. Clinical Research, April 1981.
• Dore RK, Nies KM, Iwaki Y, Louie JS, Terasaki P: “A Profile of Lymphocytotoxic Antibodies in Systemic Lupus Erythematosus”. American Rheumatism National Meetings, AtlantaGA, May 1980 (Read by Title only.)
• King DF, Dore RK, Gilbert DJ, Gurevitch AW, and Hirosi FM: Generalized Morphia with Peripheral Eosinophilic Fasciitis and Myositis. International J. Dermatol19:149‑154, April 1980.